Literature DB >> 16846553

Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective.

Charles E Lamb1, Paul H Ratner, Clarion E Johnson, Ambarish J Ambegaonkar, Ashish V Joshi, David Day, Najah Sampson, Benjamin Eng.   

Abstract

OBJECTIVE: To evaluate the cost of lost productivity in the workplace due to allergic rhinitis compared to other selected medical conditions from an employer perspective. SETTING AND PARTICIPANTS: A total of 8267 US employees at 47 employer locations who volunteered to participate in health/wellness screenings. MEASUREMENTS: The Work Productivity Short Inventory was used to assess the impact of a predefined group of health conditions on workplace productivity for the previous 12 months. Both absenteeism and presenteeism (lost productivity while at work) were recorded. Costs were calculated using a standard hourly wage.
RESULTS: Allergic rhinitis was the most prevalent of the selected conditions; 55% of employees reported experiencing allergic rhinitis symptoms for an average of 52.5 days, were absent 3.6 days per year due to the condition, and were unproductive 2.3 h per workday when experiencing symptoms. The mean total productivity (absenteeism + presenteeism) losses per employee per year were 593 US dollars for allergic rhinitis, 518 US dollars for high stress, 277 US dollars for migraine, 273 US dollars for depression, 269 US dollars for arthritis/rheumatism, 248 US dollars for anxiety disorder, 181 US dollars for respiratory infections, 105 US dollars for hypertension or high blood pressure, 95 US dollars for diabetes, 85 US dollars for asthma, and 40 US dollars for coronary heart disease. The mean total productivity loss per employee per year due to caregiving was 102 US dollars for pediatric respiratory infections, 85 US dollars for pediatric allergies, 49 US dollars for Alzheimer's disease, and 42 US dollars for otitis media/earache.
CONCLUSIONS: Allergies are major contributors to the total cost of health-related absenteeism and presenteeism. Payers and employers need to consider this when determining health benefits for employees.

Entities:  

Mesh:

Year:  2006        PMID: 16846553     DOI: 10.1185/030079906X112552

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  65 in total

1.  A mechanistic modeling system for estimating large scale emissions and transport of pollen and co-allergens.

Authors:  Christos Efstathiou; Sastry Isukapalli; Panos Georgopoulos
Journal:  Atmos Environ (1994)       Date:  2011-04-01       Impact factor: 4.798

2.  Persistent asthma, comorbid conditions and the risk of work disability: a prospective cohort study.

Authors:  R Hakola; P Kauppi; T Leino; A Ojajärvi; J Pentti; T Oksanen; T Haahtela; M Kivimäki; J Vahtera
Journal:  Allergy       Date:  2011-09-29       Impact factor: 13.146

Review 3.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

Review 4.  Employee health and presenteeism: a systematic review.

Authors:  Alyssa B Schultz; Dee W Edington
Journal:  J Occup Rehabil       Date:  2007-07-25

Review 5.  The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research.

Authors:  Wayne N Burton; Stephen H Landy; Kristen E Downs; M Chris Runken
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

6.  Allergenic pollen season variations in the past two decades under changing climate in the United States.

Authors:  Yong Zhang; Leonard Bielory; Zhongyuan Mi; Ting Cai; Alan Robock; Panos Georgopoulos
Journal:  Glob Chang Biol       Date:  2014-11-07       Impact factor: 10.863

7.  Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms.

Authors:  Michael J Goodman; Mehul Jhaveri; Kim Saverno; Kellie Meyer; Brian Nightengale
Journal:  Am Health Drug Benefits       Date:  2008-10

8.  Economic Evaluation of Quality-of-Life Improvement with Second-Generation Antihistamines and Montelukast in Patients with Allergic Rhinitis.

Authors:  Kim R Saverno; Brian Seal; Michael J Goodman; Kellie Meyer
Journal:  Am Health Drug Benefits       Date:  2009-11

Review 9.  [Costs of allergic diseases and saving potential by allergen-specific immunotherapy : A personal assessment].

Authors:  L Klimek; A M Chaker; R Mösges
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

10.  Bayesian Analysis of Climate Change Effects on Observed and Projected Airborne Levels of Birch Pollen.

Authors:  Yong Zhang; Sastry Isukapalli; Leonard Bielory; Panos Georgopoulos
Journal:  Atmos Environ (1994)       Date:  2012-11-12       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.